Could a fatty acid drug stop dangerous sugar crashes in rare disease?
NCT ID NCT07097311
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests a drug called triheptanoin, already approved for similar conditions, to see if it can prevent dangerously low blood sugar in people with MCADD, a rare inherited disorder. About 24 participants aged 4 and older will take the medication and be monitored for safety and how long their blood sugar stays stable. The goal is to find a new way to manage this condition and reduce the risk of hypoglycemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, 15224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Could a liver drug help kids and adults with rare metabolic disorder?
- Small study tests exercise safety in kids with MCADD
- Fatty acid study aims to unlock secrets of rare metabolic disease
- Could a fatty acid drug stop dangerous sugar crashes in rare disease?
- Could a urea cycle drug help MCAD patients fast longer?